|
|
SPOT ON
|
|
MSD: dangers of rofecoxib concealed for years
|
|
|
THERAPIES FROM A CRITICAL VIEW POINT
|
|
Clopidogrel (ISCOVER, PLAVIX): how long after angioplasty?
Slow-release nifedipine for angina pectoris?
|
|
|
NEW ON THE MARKET
|
|
Labelling of new drugs in the a-t
Duloxetine (YENTREVE) for urinary stress incontinence
|
|
|
REVIEW
|
|
How far is influenza vaccination evidence-based? |
|
|
a-t READERS' QUESTIONS AND COMMENTS
|
|
Is WICK ERSTE ABWEHR effective?
Insulin glargine (LANTUS): worsening of retinopathies?
|
|
|
IN BRIEF
|
|
USA: No licence for Ximelagatran (EXANTA)
Glucocorticoids increase mortality in severe head injury
Lactobacillus does not prevent post-antibiotic vulvovaginal candidiasis
Once again: quality problems of drugs used in traditional Chinese medicine (TCM)
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Hair loss after hexavalent vaccine (HEXAVAC)
Addendum: double reporting of a tolperisone-induced drug reaction (MYDOCALM)
|
|
|
SIDE EFFECTS
|
|
Cox-2-inhibitors and cardiovascular toxicity
|
|
|
DOCUMENTATION
|
|
Rise and fall of rofecoxib (VIOXX)
|
|